EVALUATION OF A TRIS-GLYCINE BUFFER MODIFICATION FOR ANTICOMPLEMENTARY ACTIVITY TESTING OF IMMUNOGLOBULIN G PREPARATIONS
Biotechnologia Acta · 30.04.2026 · 19 (3) · 32-45
DOI: 10.15407/biotech19.03.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnologia Acta, online erschienen am 30.04.2026. Verfasst von O.V. Yatsenko. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Polyvalent human intravenous immunoglobulin (IVIG) is a complex protein preparation obtained from human plasma and requires strict quality control to ensure safety and clinical efficacy. One important quality attribute is anticomplementary activity (ACA), which reflects the potential of immunoglobulin preparations to activate the complement system.
Aim
The study aimed to assess the applicability of the Tris-glycine buffer as an alternative to the pharmacopoeial barbital buffer and to provide practical guidance for laboratories performing ACA testing.
Methods
Тwo approaches for determining ACA were evaluated: the method described in the European Pharmacopeia (Ph. Eur.) and a modified procedure using a Tris-glycine buffer. Тwo approaches for determining ACA were evaluated: the method described in the European Pharmacopeia (Ph. Eur.) and a modified procedure using a Tris-glycine buffer. The tested immunoglobulins were obtained by fractionation of donor blood plasma (de-identified blood samples). Complement activity was evaluated by determining the degree of hemolysis of activated complement. ACA was assayed according to the method described in Ph. Eur. 01/2018:20617 by calculating the ratio of the activity of bound complement in the tested sample (solutions of the preparation and standard samples) to its output activity in the control sample. Data were analyzed using linear regression and a two-tailed Student's t-test (Microsoft Excel).
Results
We tested the Tris-glycine buffer-based modification for the ACA assay. The methodology was effectively reproduced and verified to meet the requirements specified in the Ph. Eur. monograph 01/2018:20617. In addition, the workflow has been optimized, increasing analytical productivity by using deep-well plates instead of individual microtubes, reducing hands-on time, and improving reproducibility by minimizing operator-dependent variability. Ноwever, when barbital buffer is replaced with a Tris-glycine buffer, samples must be adjusted to pH 7.0 before analysis, as the buffering capacity of Tris-glycine is insufficient to maintain a stable pH in the reaction mixture. Under these conditions, all tested samples met the acceptance criteria, with ACA values below 50% (less than 1 CH50/mL per 1 mg of immunoglobulin), indicating minimal complement activation.
Conclusion
The proposed modification represents a practical optimization of the known method, the AСA assay. It facilitates more efficient and reproducible testing in quality control laboratories, while maintaining compliance with established safety criteria for immunoglobulin G preparations.
Zitieren
APA
Yatsenko, O. (2026). EVALUATION OF A TRIS-GLYCINE BUFFER MODIFICATION FOR ANTICOMPLEMENTARY ACTIVITY TESTING OF IMMUNOGLOBULIN G PREPARATIONS. Biotechnologia Acta, 19(3), 32-45. https://doi.org/10.15407/biotech19.03.032
Vancouver
Yatsenko O. EVALUATION OF A TRIS-GLYCINE BUFFER MODIFICATION FOR ANTICOMPLEMENTARY ACTIVITY TESTING OF IMMUNOGLOBULIN G PREPARATIONS. Biotechnologia Acta. 2026;19(3):32-45. doi:10.15407/biotech19.03.032
BibTeX
@article{Yatsenko2026,
author = {Yatsenko, O.V.},
title = {EVALUATION OF A TRIS-GLYCINE BUFFER MODIFICATION FOR ANTICOMPLEMENTARY ACTIVITY TESTING OF IMMUNOGLOBULIN G PREPARATIONS},
journal = {Biotechnologia Acta},
year = {2026},
volume = {19},
number = {3},
pages = {32--45},
doi = {10.15407/biotech19.03.032}
}
EUVIMED